Whether you were a biotech seeking speed or a pharma managing complexity, this summit gave you the frameworks and partnerships you needed to deliver on recruitment and retention. Explore how AI-driven identification, culturally tailored education, and advocacy-led collaboration helped to transform trial delivery for dispersed and underserved populations in 2025.
Having trouble downloading the brochure? Let us know and we'll email it you instead
Download Here:
Reducing recruitment costs and boosting ROI by harnessing AI to rapidly identify and accurately target eligible rare disease patients, cutting enrollment timelines and minimizing screen failures.
Charles Shiner, Associate Vice President, Gene Therapy Marketing, Rocket Pharmaceuticals
Navigating decentralized trials in rare disease - identifying what works, tackling challenges, and balancing virtual convenience with medical oversight.
Matt Hay, U.S. Director of Advocacy for Metabolics - Neurofibromatosis (NF) and Hypophosphatasia (HPP), Alexion Pharmaceuticals
Planning for retention by embedding patient-friendly reimbursement and support strategies early - overcoming cross-border challenges, enhancing patient care with concierge and home nursing services, and simplifying communication to reduce stress.
Deborah Micklos, Senior Clinical Operations Director, Inventiva
New 2025 Companies:
